Sander R. Piersma, Karin de Punder, Joen Luirink, Nicole N. van der Wel, Laleh Majlessi, Zora Soprova, Corinne M. ten Hagen-Jongman, Tristan Felix, Connie R. Jimenez, Jan-Willem de Gier, Maria H. Daleke-Schermerhorn, Joep Beskers, Thang V. Pham, Wouter S. P. Jong, David Vikström, Frank Follmann, Thomas Baumgarten, Peter van Ulsen, Claude Leclerc, Molecular Microbiology, AIMMS, LaserLaB - Analytical Chemistry and Spectroscopy, Section Molecular Microbiology, Department of Molecular Cell Biology, Faculty of Earth and Life Sciences, VU University, Abera Bioscience, Régulation Immunitaire et Vaccinologie, Institut Pasteur [Paris]-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), Center for Biomembrane Research, Department of Biochemistry and Biophysics, Stockholm University, Xbrane Bioscience, Xbrane Bioscience (AB), Chlamydia Vaccine Research, Department of Infectious Disease Immunology, Statens Serum Institut [Copenhagen], The Netherlands Cancer Institute, Antonie van Leeuwenhoek Hospital, Department of Medical Oncology, OncoProteomics Laboratory, VU University Medical Center [Amsterdam], The research leading to these results has received funding from the EuropeanUnion’s Seventh Framework Programme (FP7/2007-2013) undergrant agreement number 280873 ADITEC. In addition, W.S.P.J. was supportedby a grant from the Dutch Technology Foundation, and Z.S. wassupported by a Mosaic Grant from the Netherlands Organization for ScientificResearch., European Project: 280873,EC:FP7:HEALTH,FP7-HEALTH-2011-single-stage,ADITEC(2011), Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut Pasteur [Paris], Institut Pasteur [Paris] (IP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), Medical oncology laboratory, and CCA - Immuno-pathogenesis
Outer membrane vesicles (OMVs) are spherical nanoparticles that naturally shed from Gram-negative bacteria. They are rich in immunostimulatory proteins and lipopolysaccharide but do not replicate, which increases their safety profile and renders them attractive vaccine vectors. By packaging foreign polypeptides in OMVs, specific immune responses can be raised toward heterologous antigens in the context of an intrinsic adjuvant. Antigens exposed at the vesicle surface have been suggested to elicit protection superior to that from antigens concealed inside OMVs, but hitherto robust methods for targeting heterologous proteins to the OMV surface have been lacking. We have exploited our previously developed hemoglobin protease (Hbp) autotransporter platform for display of heterologous polypeptides at the OMV surface. One, two, or three of the Mycobacterium tuberculosis antigens ESAT6, Ag85B, and Rv2660c were targeted to the surface of Escherichia coli OMVs upon fusion to Hbp. Furthermore, a hypervesiculating Δ tolR Δ tolA derivative of attenuated Salmonella enterica serovar Typhimurium SL3261 was generated, enabling efficient release and purification of OMVs decorated with multiple heterologous antigens, exemplified by the M. tuberculosis antigens and epitopes from Chlamydia trachomatis major outer membrane protein (MOMP). Also, we showed that delivery of Salmonella OMVs displaying Ag85B to antigen-presenting cells in vitro results in processing and presentation of an epitope that is functionally recognized by Ag85B-specific T cell hybridomas. In conclusion, the Hbp platform mediates efficient display of (multiple) heterologous antigens, individually or combined within one molecule, at the surface of OMVs. Detection of antigen-specific immune responses upon vesicle-mediated delivery demonstrated the potential of our system for vaccine development.